Overweight and Risk of Recurrence Following Neoadjuvant Chemotherapy in Breast Cancer
Clinical Breast Cancer · 2025
DOI: 10.1016/j.clbc.2025.06.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Anders Lerche Møller und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Department of Oncology, Aarhus University/Aarhus University Hospital, Central Denmark Region, Denmark; Steno Diabete…. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Overweight. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Having overweight is increasingly recognized as a risk factor for poor breast cancer (BC) outcomes. Previous studies have linked high body mass index (BMI) to an increased risk of recurrence and higher mortality. While most research has focused on patients treated with adjuvant chemotherapy, this study examines the impact of overweight on recurrence-free survival (RFS) in BC patients treated with neoadjuvant chemotherapy (NACT). MATERIALS AND METHODS: This study included 490 Swedish BC patients who completed NACT between 2005 and 2019. During a follow-up period averaging 5 years, 116 patients (24%) experienced recurrences at any location. The association between overweight (BMI ≥ 25 kg/m2) at BC diagnosis and RFS was analysed using univariable and multivariable Cox regression models. RESULTS: The majority of patients (56%, 275/490) were classified as overweight. Patients with overweight tended to present with slightly more advanced disease stages and were more likely to have ER-/HER2- BC. Multivariable Cox regression analysis, adjusted for age and menopausal status, revealed that patients with overweight had a 47% higher hazard of recurrence compared to patients without overweight (hazard ratio [HR] 1.47, 95% CI 1.01-2.15). Subgroup analysis showed the largest relative effect in the ER+/HER2+ subgroup. Notably, the association between overweight and recurrence appeared independent of whether pathological complete response was achieved. CONCLUSIONS: Overweight was associated with a higher risk of recurrence following NACT. Future research should explore whether BC prognosis can be improved by addressing modifiable factors that may mediate the impact of overweight on recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine, Department of Oncology, Aarhus University/Aarhus University Hospital, Central Denmark Region, Denmark; Steno Diabetes Centre Aarhus, Aarhus University Hospital, Central Denmark Region, D…
- Department of Clinical Medicine, Department of Oncology, Aarhus University/Aarhus University Hospital, Central Denmark Region, Denmark; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden.
- Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, Sweden.
Zitieren
APA
Møller, A. L., Borgquist, S., & Skarping, I. (2025). Overweight and Risk of Recurrence Following Neoadjuvant Chemotherapy in Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.06.009
Vancouver
Møller AL, Borgquist S, Skarping I. Overweight and Risk of Recurrence Following Neoadjuvant Chemotherapy in Breast Cancer. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.06.009
BibTeX
@article{Mller2025,
author = {Møller, Anders Lerche and Borgquist, Signe and Skarping, Ida},
title = {Overweight and Risk of Recurrence Following Neoadjuvant Chemotherapy in Breast Cancer},
journal = {Clinical Breast Cancer},
year = {2025},
doi = {10.1016/j.clbc.2025.06.009}
}
EUVIMED